Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance therapy for newly-diagnosed and platinum-sensitive recurrent ovarian cancer with BRCA mutational status: a systematic review and network meta-analysis

References

• Huang J, Chan WC, Ngai CH, et al. Worldwide burden, risk factors, and temporal trends of ovarian cancer: a global study. Cancers (Basel). 2022;14(9):2230. doi: 10.3390/cancers14092230
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi24–32. doi: 10.1093/annonc/mdt333
   PubMed Web of Science ®Google Scholar
• Musolino A, Bella MA, Bortesi B, et al. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study. Breast. 2007;16(3):280–292. doi: 10.1016/j.breast.2006.12.003
   PubMed Web of Science ®Google Scholar
• Mylavarapu S, Das A, Roy M. Role of BRCA mutations in the modulation of response to platinum therapy. Front Oncol. 2018;8:16. doi: 10.3389/fonc.2018.00016
   PubMed Web of Science ®Google Scholar
• Manchana T, Phoolcharoen N, Tantbirojn P. BRCA mutation in high grade epithelial ovarian cancers. Gynecol Oncol Rep. 2019;29:102–105. doi: 10.1016/j.gore.2019.07.007
   PubMed Web of Science ®Google Scholar
• Purwar R, Ranjan R, Pal M, et al. Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trials. World J Surg Onc. 2023;21(1):157. doi: 10.1186/s12957-023-03027-4
   PubMed Web of Science ®Google Scholar
• Rose M, Burgess JT, O’Byrne K, et al. PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance. Front Cell Dev Biol. 2020;8:564601. doi: 10.3389/fcell.2020.564601
   PubMed Web of Science ®Google Scholar
• Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154–2164. doi: 10.1056/NEJMoa1611310
   PubMed Web of Science ®Google Scholar
• Dougherty BA, Lai Z, Hodgson DR, et al. Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting. Oncotarget. 2017;8(27):43653–43661. doi: 10.18632/oncotarget.17613
   PubMedGoogle Scholar
• Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274–1284. doi: 10.1016/S1470-2045(17)30469-2
   PubMed Web of Science ®Google Scholar
• Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495–2505. doi: 10.1056/NEJMoa1810858
   PubMed Web of Science ®Google Scholar
• Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949–1961. doi: 10.1016/S0140-6736(17)32440-6
   PubMed Web of Science ®Google Scholar
• Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic pancreatic cancer: ASCO guideline update. J Clin Oncol. 2020;JCO2001364:3217–3230.
   Google Scholar
• Jiang Y, Zhao J, Zhang L, et al. Evaluation of the efficacy and safety of PARP inhibitors in advanced-stage epithelial ovarian cancer. Front Oncol. 2020;10:954. doi: 10.3389/fonc.2020.00954
   PubMed Web of Science ®Google Scholar
• Ruscito I, Bellati F, Ray-Coquard I, et al. Incorporating parp-inhibitors in primary and recurrent ovarian cancer: a meta-analysis of 12 phase II/III randomized controlled trials. Cancer Treat Rev. 2020;87:102040. doi: 10.1016/j.ctrv.2020.102040
   PubMed Web of Science ®Google Scholar
• Gupta S, Nag S, Aggarwal S, et al. Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives – a review. J Ovarian Res. 2019;12(1):103. doi: 10.1186/s13048-019-0579-0
   PubMed Web of Science ®Google Scholar
• Research C for DE and. FDA approves niraparib for first-line maintenance of advanced ovarian cancer. FDA [Internet]. 2021 [cited 2022 Oct 10]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer
   Google Scholar
• Research C for DE and. FDA approved olaparib (LYNPARZA, AstraZeneca Pharmaceuticals LP) for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBrcam or sBrcam) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based. FDA [Internet]. 2019 [cited 2022 Oct 10]. Available from: https://www.fda.gov/drugs/fda-approved-olaparib-lynparza-astrazeneca-pharmaceuticals-lp-maintenance-treatment-adult-patients
   Google Scholar
• Research C for DE and Niraparib (ZEJULA). FDA [Internet]. 2019 [cited 2022 Oct 10]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/niraparib-zejula
   Google Scholar
• Research C for DE and. FDA approves rucaparib for maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer. FDA [Internet]. 2019 [cited 2022 Oct 10]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-rucaparib-maintenance-treatment-recurrent-ovarian-fallopian-tube-or-primary-peritoneal
   Google Scholar
• Valabrega G, Scotto G, Tuninetti V, et al. Differences in PARP inhibitors for the treatment of ovarian cancer: mechanisms of action, pharmacology, safety, and efficacy. Int J Mol Sci. 2021;22(8):4203. doi: 10.3390/ijms22084203
   PubMed Web of Science ®Google Scholar
• Li N, Bu H, Liu J, et al. An open-label, multicenter, single-arm, phase II study of fluzoparib in patients with Germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian cancer. Clin Cancer Res. 2021;27(9):2452–2458. doi: 10.1158/1078-0432.CCR-20-3546
   PubMed Web of Science ®Google Scholar
• Li N, Zhang Y, Wang J, et al. Fuzuloparib maintenance therapy in patients with platinum-sensitive, recurrent ovarian carcinoma (FZOCUS-2): a multicenter, randomized, double-blind, placebo-controlled, phase III trial. J Clin Oncol. 2022;40(22):2436–2446. doi: 10.1200/JCO.21.01511
   PubMed Web of Science ®Google Scholar
• Coleman RL, Fleming GF, Brady MF, et al. Veliparib with First-Line Chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med. 2019;381(25):2403–2415. doi: 10.1056/NEJMoa1909707
   PubMed Web of Science ®Google Scholar
• Boussios S, Abson C, Moschetta M, et al. Poly (ADP-Ribose) polymerase inhibitors: talazoparib in ovarian cancer and beyond. Drugs R D. 2020;20(2):55–73. doi: 10.1007/s40268-020-00301-8
   PubMed Web of Science ®Google Scholar
• Ying Z, Qi D, Chaoran W, et al. PARP inhibitors rising as an epoch-making strategy in first-line maintenance therapy of ovarian cancer: a systematic review and meta-analysis. Cancer Invest. 2022;40(10):889–900. doi: 10.1080/07357907.2022.2088780
   PubMed Web of Science ®Google Scholar
• Gulia S, Kannan S, Ghosh J, et al. Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis. ESMO Open. 2022;7(5):100558. doi: 10.1016/j.esmoop.2022.100558
   PubMed Web of Science ®Google Scholar
• Ibrahim EM, Refae AA, Bayer AM, et al. Poly(adp-ribose) polymerase inhibitors as maintenance treatment in patients with newly diagnosed advanced ovarian cancer: a meta-analysis. Future Oncol. 2020;16(10):585–596. doi: 10.2217/fon-2020-0057
   PubMed Web of Science ®Google Scholar
• Wang Y, Ren F, Song Z, et al. PARP inhibitors in patients with newly diagnosed advanced ovarian cancer: a meta-analysis of randomized clinical trials. Front Oncol. 2020;10:1204. doi: 10.3389/fonc.2020.01204
   PubMed Web of Science ®Google Scholar
• Xu Y, Ding L, Tian Y, et al. Comparative efficacy and safety of PARP inhibitors as maintenance therapy in platinum sensitive recurrent ovarian cancer: a network meta-analysis. Front Oncol. 2020;10:573801. doi: 10.3389/fonc.2020.573801
   PubMed Web of Science ®Google Scholar
• Wang H, Wu M, Liu H, et al. Comparison of the efficacy and safety of PARP inhibitors as a monotherapy for platinum-sensitive recurrent ovarian cancer: a network meta-analysis. Front Oncol. 2021;11:785102. doi: 10.3389/fonc.2021.785102
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med. 2009;6(7):e1000097. doi: 10.1371/journal.pmed.1000097
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12. doi: 10.1016/0197-2456(95)00134-4
   PubMedGoogle Scholar
• Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med. 2001;135(11):982–989. doi: 10.7326/0003-4819-135-11-200112040-00010
   PubMed Web of Science ®Google Scholar
• Poveda A, Floquet A, Ledermann JA, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(5):620–631. doi: 10.1016/S1470-2045(21)00073-5
   PubMed Web of Science ®Google Scholar
• Wu XH, Zhu JQ, Yin RT, et al. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆. Ann Oncol. 2021;32(4):512–521. doi: 10.1016/j.annonc.2020.12.018
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382–1392. doi: 10.1056/NEJMoa1105535
   PubMed Web of Science ®Google Scholar
• Monk BJ, Parkinson C, Lim MC, et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol. 2022;JCO2201003:3952–3964.
   Google Scholar
• Li N, Zhu J, Yin R, et al. Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME study): a randomized, double-blind, placebo-controlled, phase 3 trial (LBA 5). Gynecol Oncol [Internet] 2022;166:S50–S51. [cited 2022 Nov 21]. Available from: https://www.sciencedirect.com/science/article/pii/S0090825822012987 10.1016/S0090-8258(22)01298-7.
   PubMed Web of Science ®Google Scholar
• González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391–2402. doi: 10.1056/NEJMoa1910962
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416–2428. doi: 10.1056/NEJMoa1911361
   PubMed Web of Science ®Google Scholar
• Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in pat… OncologyPro [Internet]. [cited 2022 Nov 21]. Available from: https://oncologypro.esmo.org/meeting-resources/esmo-congress/final-overall-survival-os-results-from-the-phase-iii-paola-1-engot-ov25-trial-evaluating-maintenance-olaparib-ola-plus-bevacizumab-bev-in-pat.
   Google Scholar
• Banerjee S, Moore KN, Colombo N, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1721–1731. doi: 10.1016/S1470-2045(21)00531-3
   PubMed Web of Science ®Google Scholar
• Wu L, Zhu J, Yin R, et al. Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort. Gynecol Oncol. 2021;160(1):175–181. doi: 10.1016/j.ygyno.2020.10.005
   PubMed Web of Science ®Google Scholar
• Coleman RL, Oza AM, Lorusso D, et al. RA-249-ESGO overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. IJGC [Internet]. 2022;32. [cited 2022 Nov 21]. Available from: https://ijgc.bmj.com/content/32/Suppl_2/A226.1
   Google Scholar
• Matulonis U, Herrstedt J, Oza A, et al. Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer. Gynecol Oncol [Internet] 2021;162:S24–S25. [cited 2022 Nov 21]. Available from: https://www.sciencedirect.com/science/article/pii/S0090825821006934 10.1016/S0090-8258(21)00693-4
   PubMed Web of Science ®Google Scholar
• Tomao F, Bardhi E, Di Pinto A, et al. Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials according to BRCA mutational status. Cancer Treat Rev. 2019;80:101909. doi: 10.1016/j.ctrv.2019.101909
   PubMed Web of Science ®Google Scholar
• Lin Q, Liu W, Xu S, et al. PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a meta-analysis. BJOG. 2021;128(3):485–493. doi: 10.1111/1471-0528.16411
   PubMed Web of Science ®Google Scholar
• Bartoletti M, Pelizzari G, Gerratana L, et al. Bevacizumab or PARP-Inhibitors maintenance therapy for platinum-sensitive recurrent ovarian cancer: a network meta-analysis. Int J Mol Sci. 2020;21(11):E3805. doi: 10.3390/ijms21113805
   PubMed Web of Science ®Google Scholar
• Feng Y, Huang H, Wan T, et al. Comparison of PARPis with angiogenesis inhibitors and chemotherapy for maintenance in ovarian cancer: a network meta-analysis. Adv Ther. 2019;36(12):3368–3380. doi: 10.1007/s12325-019-01106-1
   PubMed Web of Science ®Google Scholar
• Miller RE, El-Shakankery KH, Lee J-Y. PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies. J Gynecol Oncol. 2022;33(3):e44. doi: 10.3802/jgo.2022.33.e44
   PubMed Web of Science ®Google Scholar
• Luo J, Ou S, Wei H, et al. Comparative efficacy and safety of poly (ADP-Ribose) polymerase inhibitors in patients with ovarian cancer: a systematic review and network meta-analysis. Front Oncol. 2022;12:815265. doi: 10.3389/fonc.2022.815265
   PubMed Web of Science ®Google Scholar
• Pandey P, Sahoo RK. Myeloid neoplasms on poly (ADP-ribose) polymerase inhibitor therapy. IJMIO. 2022;7:98–101. doi: 10.25259/IJMIO_20_2022
   Google Scholar